Price
CHART BY
Frequently asked questions
What is Innoviva's market capitalization?
The market capitalization of Innoviva is $1.53B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is Innoviva's Price-to-Earnings (P/E) ratio?
The Price-to-Earnings (P/E) ratio (TTM) for Innoviva is 5.15. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
What is the Earnings Per Share (EPS) for Innoviva?
Innoviva's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $4.105. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Innoviva's stock?
Currently, 4 analysts cover Innoviva's stock, with a consensus target price of $35.00. Analyst ratings provide insights into the stock's expected performance.
What is Innoviva's revenue over the trailing twelve months?
Over the trailing twelve months, Innoviva reported a revenue of $453.80M.
What is the EBITDA for Innoviva?
Innoviva's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $203.00M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Innoviva?
Innoviva has a free cash flow of $189.44M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Innoviva have, and what sector and industry does it belong to?
Innoviva employs approximately 159 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Innoviva's shares?
The free float of Innoviva is 71.34M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $1.53B
- EPS (TTM)
- $4.105
- Free Float
- 71.34M
- P/E ratio (TTM)
- 5.15
- Revenue (TTM)
- $453.80M
- EBITDA (TTM)
- $203.00M
- Free Cashflow (TTM)
- $189.44M
Pricing
- 1D span
- $20.47$21.00
- 52W span
- $16.52$25.02
Analyst Ratings
The price target is $35.00 and the stock is covered by 4 analysts.
Buy
3
Hold
0
Sell
1
Information
Innoviva, Inc. engages in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.
- Employees
- 159
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- INVA
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet